Clinical trial NCT04511871: A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Official title: A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Solid Tumor
Gastric Cancer
Breast Cancer
Ovarian Cancer
Sarcoma
Keywords: HER2
CAR-T
Solid tumors
Lead sponsor: Shanghai PerHum Therapeutics Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Shanghai Zhongshan Hospital
First posted: 2020-08-13
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This clinical study is to investigate the safety and tolerability of CCT303-406 CAR modified autologous T cells (CCT303-406) in subjects with relapsed or refractory stage IV metastatic HER2-positive solid tumors.

Detailed description: This is a single arm, open label, dose escalation clinical study to evaluate the safety and preliminary therapeutic efficacy of CCT303-406 cells in adult subjects with HER2 positive relapsed or refractory stage IV metastatic solid tumors.

Subjects that meet inclusion criteria with positive biopsy HER2 (IHC 3+ in ≥50% tumor cells) will receive CCT303-406 according to the 3+3 dose escalation design.

Eligibility criteria: Inclusion Criteria:

1. Patients with willingness to be in the study and follow all study procedures, and capable of providing informed consent
2. Male or female aged 18-70 years
3. Patients with stage IV (according to the 8th edition of AJCC) advanced solid tumor malignancies that have failed standard treatment of relapsed or difficult-to-treat solid tumors confirmed by histology or cytology
4. At least one measurable lesion, i.e. the length of non-lymph node lesions examined according to CT cross-sectional scanning or magnetic resonance imaging (MRI), or the short diameter of the lymph node lesions is ≥15 mm according to RECIST 1.1
5. Tumors with HER2 IHC 3+ in≥50% of all tumor cells as determined by IHC according to the Breast Cancer HER2 Testing (2019 edition) and the Gastric Cancer HER2 Testing (2016 edition); For HER2 IHC 3+ tumors other than gastric and breast cancers, FISH is required to confirm HER2 expression; For relapsed patients after HER2-targeted therapies, biopsy and IHC are required to confirm HER2 expression per enrollment criteria.
6. ECOG Performance Status 0-1
7. Expected survival greater than 12 weeks
8. Adequate organ and hematopoietic system functions to meet the following requirements:

   * Hemoglobin (HGB) s 90 g/L, no blood transfusions within two weeks;
   * White blood cell (WBC) count≥2.5×109/L
   * Absolute Neutrophil Count (ANC) ≥1.5 x 109/L
   * Platelet (PLT) count ≥80-109/L
   * Total bilirubin (TBIL) ≤3.0ng/dL or ≤5 ULN
   * ALT and AST ≤5 ULN; for liver metastasis, ALT and AST ≤5 ULN
   * Creatinine (Cr) ≤1.5 x ULN; or creatinine removal rate (CrCl) ≥50 mL/min
9. LVEF≥50%
10. Serum troponin T \<0.03 ng/mL
11. PT: INR \< 1.7 or extended PT to normal value \< 4s
12. Normal language, recognition and consciousness assessed by investigator during screening phase
13. Capable of receiving treatment and follow-up, including treatment in the clinical center;
14. Female subjects of childbearing age must take acceptable measures to minimize the likelihood of pregnancy during the trial. The results of serum or urine pregnancy test must be negative
15. Female subjects must not be in the lactation period.

Exclusion Criteria:

1. Females with pregnancy or in lactation period
2. Patients with active hepatitis B, or active hepatitis C
3. HIV positive
4. Other active infections of clinical significance
5. Patients receiving in situ surgery within 3 months
6. Patients with the following previous or accompanying diseases:

   • Patients diagnosed as severe autoimmune diseases that require long term (more than 2 months) treatment with systemic immunosuppressants (steroids), or diseases with immune-mediated symptoms, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), and autoimmune vasculitis
7. Patients with ≥Grade 2 peripheral neuronal diseases (according to NCI-CTCAE v5.0)
8. Patients with any mental illness, including dementia, mental changes, which may cause difficulties understanding the informed consent and related questionnaires
9. Patients with serious uncontrollable diseases, which may interfere with the therapies in this study
10. Patients with other active malignancies in the past 5 years excluding those with completely cured basal or squamous skin cancers, superficial bladder cancers or primary breast cancers without need of follow-up treatment
11. Patients receiving systemic steroids or steroid inhalants
12. Patients who have received tumor immunotherapy (including monoclonal antibody or cell therapy) in the past 4 weeks
13. Patients allergic to immunotherapies or related drugs
14. Patients with metastatic lesions in meninges or central nervous system, or clear evidence of central nervous system diseases with continous significant symptoms in the last 6 months
15. Patients with NYHA class II heart failure, or hypertension incontrollable by standard care, or medical history of myocarditis, or heart attack within a year
16. Patients who have received or are going to receive organ transplantation
17. Patients with active bleeding
18. Patients with incontrollable pleural or abdominal fluid that needs clinical treatment or intervention
19. Patients having undergone major surgery within 4 weeks or have not fully recovered from prior surgery
20. Patients that have received radiotherapy within 4 weeks, excluding those who received local irradiation for the peripheral bone metastatic lesions for more than 2 weeks, and recovered from all acute toxicities of radiotherapy
21. Patients that have received anthracyclines within 8 weeks
22. Patients as determined by the investigators to be inappropriate for the study

Primary outcomes:
measure: MTD: to determine the maximum tolerated dose of CCT303-406
timeFrame: 28 days following infusion
Secondary outcomes:
measure: ORR (overall response rate): Proportion of subjects with the best overall response (BOR)
timeFrame: Up to 52 weeks
measure: 12 month survival rate
timeFrame: Up to 52 weeks
measure: DCR: Disease control rate
timeFrame: Up to 52 weeks
measure: DOR: Duration of reponse
timeFrame: Up to 52 weeks
measure: PFS: Progression free survival
timeFrame: Up to 52 weeks
measure: AE: Adverse Events
timeFrame: Up to 52 weeks
measure: The expansion over time of genetically modified CCT303-406 cells in the peripheral blood as determined by QPCR (copies/ug gDNA)
timeFrame: Up to 52 weeks
measure: The persistence over time of genetically modified CCT303-406 cells in the peripheral blood as determined by Flow Cytometry (% CAR + cells)
timeFrame: Up to 52 weeks
Other outcomes:
measure: Exploration of target-efficacy correlation
timeFrame: Up to 52 weeks
Locations:
city: Shanghai
country: China
facility: Zhongshan Hospital Affiliated to Fudan University
state: Shanghai
Study officials:
References: